Exagen Inc.XGN

Exagen Inc. (CIK 1274737) is a diagnostics outfit that wants to be known for unlocking autoimmune mysteries with its AVISE testing platform, which includes lupus biomarker panels like CB-CAPs-broadly, a set of blood tests designed to tell lupus patients and their doctors whether inflammation is doing its usual mischief. The company sells these tests to clinics, labs, and, increasingly, to biopharma partners who need granular immune-activation data. The pitch is compelling: clarity for patients, confidence for clinicians, and a tidy revenue stream for Exagen. The question is whether the revenue stream is actually tidy enough to cover the burn. (source: Our Tests - Exagen Inc., https://exagen.com/tests/; Lupus Biomarkers - CB-CAPs, https://exagen.com/cb-caps-technology/; Biopharma Solutions - Research & Discovery - Exagen Inc., https://exagen.com/partnerships/biopharma-solutions/)

What changed this week is that the company’s 10-Q for the quarter ending 31 March 2026 landed on EDGAR, and the numbers are sobering. Revenue clocked in at $17.3 million, up 12% versus the same quarter last year-a headline that sounds like growth, until you recall the company still lost $4 million on the quarter and sucked $10.4 million out of operating cash. The balance sheet shows $52 million in assets against $37.5 million in liabilities, which leaves a shareholders’ equity of $14.4 million and a cash pile of $21.5 million that’s evaporating faster than a lupus flare-up in sunlight. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1274737/000127473726000033/rm-20260331.htm)

On the surface, Exagen is a diagnostics company with a platform (AVISE), a patented lupus test (CB-CAPs), and a growing roster of biopharma partners who pay for discovery-grade immune-activation data. The problem is that the company’s core diagnostics business is still not covering its own costs. Research and development spend was $1.6 million in the quarter, while capital spending was a mere $228,000-so the burn isn’t on shiny new machines but on the daily business of selling tests that insurers may or may not reimburse. Diluted EPS came in at -$0.17, and the weighted average share count rose to 23.9 million, up from 22.6 million in the prior comparable quarter. That means dilution is part of the growth story, not an accident. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1274737/000127473726000033/rm-20260331.htm)

The company’s own press release from 11 May 2026 trumpeted ‘record total revenue’ and guided to full-year 2026 revenue of $70 million to $73 million, which is a rounding error for a company of its ambitions. The press release quotes CEO John Aballi saying the quarter reflected ‘disciplined execution and effective revenue cycle management’-corporate-speak for ‘we cut costs and still lost money, but less than before.’ The gap between the platform story and the ledger remains a chasm. (source: Press Release dated May 11, 2026, https://www.sec.gov/Archives/edgar/data/1274737/000127473726000027/q12026exagenearningspressr.htm)

If you want to see where Exagen thinks its edge lies, look no further than its AVISE CTD test, the only diagnostic panel that incorporates CB-CAPs assays (EC4d and BC4d) and is ‘only available from Exagen.’ The marketing materials are polished, the science is specific, and the regulatory disclosures are meticulous. Yet the numbers tell a different tale: a company whose cash burn is outpacing its cash generation, whose equity cushion is thin, and whose path to profitability still looks like a brochure rather than a balance sheet. For now, the AVISE story is a triumph of promise over profit. (source: Lupus Biomarkers - CB-CAPs, https://exagen.com/cb-caps-technology/; Our Tests - Exagen Inc., https://exagen.com/tests/)

What remains unproven is whether Exagen can translate its diagnostic science into sustainable, reimbursable revenue at scale. The company’s cash and cash equivalents stood at $21.5 million at quarter-end, which sounds healthy until you consider the $10.4 million quarterly cash burn and the fact that the full-year revenue guidance implies roughly $72 million in sales-a figure that would represent less than four quarters of current cash burn at this rate. The company’s ability to secure broader reimbursement, scale its biopharma partnerships, or cut burn materially will determine whether the next filing reads like a turnaround or a tombstone. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1274737/000127473726000033/rm-20260331.htm)

For context on the company’s ownership structure, recent SEC filings show a trio of beneficial owners (identified by CIK 1782149887, 1782148287, and 1782147613) reporting transactions in early June 2026, alongside a 13G filing from 27 May 2026 and a 13G/A from 20 May 2026. These disclosures are routine, but they underscore that the company’s equity base is fluid and that large holders can move the share count without notice. The filing index on EDGAR catalogues the steady drip of submissions that keep the company’s governance theatre running, but it’s the cash ledger that tells the real story. (source: SEC EDGAR filing index for Exagen Inc., https://www.sec.gov/edgar/browse/?CIK=1274737; XGN 4 (2026-06-22) filings, https://www.sec.gov/Archives/edgar/data/1274737/000127473726000043/xslF345X06/wk-form4_1782149887.xml; XGN SCHEDULE 13G (2026-05-27), https://www.sec.gov/Archives/edgar/data/1274737/000207583326000005/xslSCHEDULE_13G_X02/primary_doc.xml)